Six months is a long time to beat an enrollment deadline, and in Celldex’s Phase 3 CSU program that margin matters: 1,939 patients across 500-plus sites in 43 countries constitutes the largest antihistamine-refractory CSU trial ever run, and the cohort deliberately includes patients who failed advanced therapies — the population that most urgently needs an alternative to omalizumab and that regulators will scrutinize hardest when the BLA lands in 2027.
Topline data from EMBARQ-CSU1 and EMBARQ-CSU2 are slated for Q4 2026. The design choices embedded in these trials carry real consequence. Enrolling patients who failed biologics raises the efficacy bar barzolvolimab must clear, but it also positions the label to read far broader than the typical “inadequate response to H1 antihistamine” carve-out that limits first-generation approvals. That breadth is where the clinical story gets structurally interesting: if the Phase 2 signals — sustained off-treatment efficacy past tryptase normalization at 52 weeks — replicate at scale, the mechanism supports a disease-modification argument that no current CSU therapy can credibly make. That argument will need to survive scrutiny in the topline package, particularly around durability endpoints.
The cold urticaria and symptomatic dermographism arm adds a distinct regulatory dimension. Barzolvolimab is the only agent with Phase 2 evidence of clinical benefit in ColdU and SD — two indications with no approved therapy — and the retreatment data showing equivalent efficacy on re-exposure directly addresses the intermittent dosing question payers will raise immediately. Phase 3 enrollment there is active now. Meanwhile, Phase 2 readouts in prurigo nodularis and atopic dermatitis are expected by late 2026, stress-testing whether mast-cell depletion via KIT inhibition extends meaningfully beyond urticaria. CDX-622, the SCF/TSLP bispecific, adds a separate mechanistic bet: simultaneous mast-cell depletion and Type 2 pathway suppression, with the proof-of-mechanism asthma study generating pharmacodynamic biomarker data that will define whether the combination is genuinely additive or redundant.
The single data point to watch in the Q4 CSU readout is not overall response rate but the responder analysis specifically in the advanced-therapy-experienced subgroup — that subset determines whether barzolvolimab secures a label that can displace, rather than merely complement, existing biologic treatment algorithms.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
